Peanut allergy is a growing concern, with a rising prevalence and a high risk of severe, even fatal, allergic reactions. Current treatment options are limited, highlighting the urgent need for new therapies. According to a study published in the Journal of Allergy and Clinical Immunology, Mabylon, a biotechnology company headquartered in Schlieren, Switzerland, is addressing this need with their innovative drug candidate, MY006.
Mabylon has developed the multispecific anti-peanut antibody by leveraging its antibody discovery platform and understanding of allergic responses. Unlike traditional single-target therapies, MY006 is a unique tri-specific molecule capable of targeting four different allergenic epitopes on major peanut allergens. This multi-pronged approach is designed to provide comprehensive protection against allergic reactions.
Early studies on MY006 have shown promising results with excellent manufacturability and safety profiles. In lab tests, MY006 was effective at inhibiting the binding of patient IgE and reducing the responsiveness of mast cells and basophils to peanut extracts. To further evaluate its effectiveness, researchers used a humanized mouse model of peanut allergy. A single subcutaneous injection of MY006 was able to prevent anaphylaxis in vivo, demonstrating its potential to protect against severe allergic reactions.
An exciting aspect of MY006 is its potential for long-term protection. The drug has been designed with half-life extension and optimal pharmacological properties. It is expected to provide continuous protection from accidental peanut exposure with just a few subcutaneous injections per year, providing significant improvement over current treatments that often require frequent administration or strict avoidance.
MY006 is currently undergoing studies in preparation for an IND (Investigational New Drug) application, which are the final preclinical tests required before human trials can begin. The company anticipates starting first-in-human trials by the end of 2025, with the goal of bringing this potentially life-changing therapy to patients in need of a safe, rapid, and long-term solution to peanut allergy. Mabylon is also planning treatments for other allergies.
